Jump to content

Baxalta

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 167.83.210.25 (talk) at 15:55, 3 June 2016 (→‎Company History). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Baxalta
Company typeSubsidiary of Shire plc
IndustryBiotechnology
Founded2015
Spun off from Baxter International
Headquarters
United States Edit this on Wikidata
ProductsHematology, Immunology, Pulmonology
Number of employees
16,000[1]
Websitewww.baxalta.com

Baxalta (Bax, taken from its former parent company and Alta taken from the Latin Altus which translates as 'high' or 'profound'[2]) was a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division.[1][3] with revenue of $6 billion.

Company History

Baxalta inherited all of its parent company's on-the-market treatments, focused on hemophilia, The company aims to launch 20 in-development projects by 2020, heaping $2.5 billion in annual sales. Before being spun off, Baxalta acquired SuppreMol for $225 million. Baxalta also acquired the blockbuster leukemia drug Oncaspar from Sigma-Tau Finanziaria S.p.A. for $900 million.[1][4]

In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company[5][6] sending the Baxalta share price up over 16%. Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36% when compared to the company's stock price as of August 3.[7] This deal would also be set to create the largest global biotech company focused solely on rare diseases.[7]

In January 2016, after 6 months of negotiations, the company agreed to be acquired by Shire for $32 billion.[8] Shareholders have approved of the transaction and the deal is planned to close on 3 June 2016.[9]

As of 3 June 2016, Shire plc has officially acquired Baxalta Inc.

Pipeline

Hematology
  • BAX 855 – long-acting pegylated full-length rFVIII[10] hemophilia A drug awaiting FDA approval in conjunction with Nektar Therapeutics.[11] It is also undergoing Phase II trials for sickle cell.[12]
  • BAX 111 – submitted as a recombinant von Willebrand factor treatment for von Willebrand disease, filed with the FDA in December 2014.[13] In August 2015, data was released and published in the journal Blood,[14] which indicated that 100 percent of the patients treated with BAX 111 were successful in the management of bleeding episodes.[15][16]
  • BAX 817 – Recombinant factor VIIa[12]
  • BAX 335 – FIX gene therapy in Phase II.[12]
  • BAX 930 – Recombinant ADAMTS13[12]
  • BAX 826 – Recombinant, extended half-life Factor VIII[12]
  • BAX 888 – Factor VIII gene therapy in Phase I trials.[12]
Immunology
Oncology
  • MM-398 – Co-developed with Merrimack Pharmaceuticals.[17] Undergoing EU reviews for post-Gemcitabine pancreatic cancer, in Phase III trials for gastric cancer[12] Currently undergoing priority review with the FDA[18] for a new drug application.[19][20]
  • Pacritinib – Phase III trials for Myelofibrosis, Phase I trials for Acute Myeloid Leukemia and pre-clinical for Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome and Polycythemia Vera.[12]
  • Rigosertib – Phase III trials for Myelodysplastic Syndrome.[12]
  • BAX 069 – also known as Imalumab, in Phase II trials for Malignant Ascites and Metastatic Colorectal cancer.[12]

References

  1. ^ a b c Ben Reynolds. "Baxalta: A Rare Undervalued Biopharmaceutical Company". cnafinance.com.
  2. ^ "An Error Occurred Setting Your User Cookie". future-science.com.
  3. ^ "Baxalta: Baxter's newly named biopharma spinout has had its ups and downs". FierceBiotech.
  4. ^ "Baxter Expands Cancer Therapies With $900M Oncaspar Buy". law360.com.
  5. ^ Tess Stynes (4 August 2015). "Shire Makes Unsolicited $30 Billion Bid for Baxalta". WSJ.
  6. ^ "Shire Offers $30B for Baxalta". GEN.
  7. ^ a b Kevin McCoy, USA TODAY (4 August 2015). "Pharma mania: Shire offers $30B for Baxalta". USA TODAY.
  8. ^ http://www.genengnews.com/gen-news-highlights/shire-baxalta-tie-the-knot-in-32b-merger/81252213/
  9. ^ DeMuth, Jr., Chris (27 May 2016). "Facebook Is Watching You". Seeking Alpha. Baxalta. Retrieved 2016-05-27.
  10. ^ "Blood Journal - Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A". bloodjournal.org.
  11. ^ "Baxalta & Nektar Reveal Full Data from Hemophilia Study - Analyst Blog". NASDAQ.com. 17 July 2015.
  12. ^ a b c d e f g h i j k l m n o p "Pharmaceutical Development Pipeline - Baxalta". baxalta.com.
  13. ^ "Baxalta's first-of-its-kind bleeding drug lines up for FDA approval". FierceBiotech.
  14. ^ "Blood Journal - Hemostatic efficacy, safety and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease". bloodjournal.org.
  15. ^ "Blood Publishes Phase III Data on Baxalta's Investigational Treatment for Von Willebrand Disease, the Most Common Type of Inherited Bleeding Disorder". Yahoo Finance. 3 August 2015.
  16. ^ "Blood Publishes Phase III Data on Baxalta's Investigational Treatment for Von Willebrand Disease, the Most Common Type of Inherited Bleeding Disorder - Business Wire". businesswire.com. 3 August 2015.
  17. ^ "MM-398". merrimackpharma.com.
  18. ^ Merrimack Pharmaceuticals, Inc. (25 June 2015). "U.S. FDA Grants Priority Review for MM-398 New Drug... -- CAMBRIDGE, Mass. and DEERFIELD, Ill., June 25, 2015 /PRNewswire/ --". prnewswire.com.
  19. ^ "U.S. FDA Grants Priority Review for MM-398 New Drug Application". merrimackpharma.com.
  20. ^ "Oncology Times". LWW.
Stub icon

This corporation or company article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Baxalta&oldid=723530933"